Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).
siliconera

FFVII Rebirth Directors Nomura and Hamaguchi Talk About Gilgamesh

The directors said that the side quest chain is titled Ancient Matters, and Gilgamesh seems to first appear on the fourth mission. When asked about the inclusion of the character in the world of FFVII ...
siliconera

Tetsuya Nomura Reveals the Origin of FFV Gilgamesh

Final Fantasy V turned thirty years old on December 6, 2022. Square Enix celebrated by turning the spotlight on one of the Final Fantasy‘s most iconic characters, Gilgamesh. In FFV, FFV‘s 30th ...
The Washington Post

In search of Gilgamesh, the epic hero of ancient Babylonia.

The oldest surviving fragments of the Babylonian epic we now call Gilgamesh date back to the 18th century -- the 18th century before the Christian era, that is, more than 3,700 years ago. Etched in ...
Nasdaq

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...